Para-aminosalicylic acid as a lipid-lowering agent

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Elevated serum lipids, including triglycerides and cholesterol, are significant risk factors for cardiovascular disease.
• Lipid-lowering diets are a primary intervention, but pharmacological agents are often necessary for optimal management.

Purpose of the Study:

• To evaluate the efficacy of para-aminosalicylic acid (PAS) in reducing serum lipoprotein lipid concentrations in patients with hyperlipidemia.
• To assess the impact of PAS on specific lipid fractions like very low-density lipoprotein (VLDL) triglycerides and low-density lipoprotein (LDL) cholesterol.

Main Methods:

• A double-blind, crossover study design was employed.
• Thirty patients adhering to a lipid-lowering diet received 6 gm of PAS daily for 4 weeks.
• Serum lipid profiles, VLDL and LDL cholesterol levels, and lipoprotein lipase activity were measured.

Main Results:

• PAS treatment resulted in a significant average reduction in serum triglyceride concentration (28%) and serum cholesterol concentration (12%).
• Significant decreases were observed in VLDL triglycerides (40%) and LDL cholesterol (6%).
• Hypercholesterolemic patients showed a 14% reduction in LDL cholesterol, while Type IV hypertriglyceridemia patients experienced a 37% reduction in serum triglycerides due to a 47% decrease in VLDL triglycerides. Unexpectedly, lipoprotein lipase activity decreased by 16%.

Conclusions:

• Para-aminosalicylic acid demonstrates significant lipid-lowering capacity, particularly for triglycerides and VLDL, in patients on dietary management.
• The drug did not adversely affect glucose tolerance or serum insulin levels.
• The observed reduction in lipoprotein lipase activity warrants further investigation regarding its clinical implications.